Biotec
Provider 
Founded 1958
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Private

Biologics development and contract manufacturing services from Brazil's first industrial-scale monoclonal antibody plant.
Biotec is Libbs Farmacêutica's biotechnology platform, inaugurated in 2016 as Brazil's first plant capable of producing monoclonal antibody medicines at industrial scale. It manufactures the rituximab and bevacizumab biological medicines and develops biosimilars to broaden access to treatments for complex diseases such as cancer and autoimmune conditions.
Beyond its own products, the unit offers technology transfer of biosimilar biologicals through partnerships with pharmaceutical companies, optimization of established bioprocesses, and contract development and manufacturing (CDMO) services covering every production stage through packaging for other companies. The multipurpose Biotec line announced for 2024 extends the platform to new technologies including messenger RNA.
| Attribute | Biotec | Biologics Contract Manufacturing | BioXcellence | WuXi Biologics CDMO | |
|---|---|---|---|---|---|
| Provider | |||||
| Founded | 1958 | 2013 | 1885 | 2014 | |
| Sells To | Consumers, Enterprise | Enterprise | Consumers, Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Recurring, Software | Recurring, Software | Recurring | |
| Ownership | Private | Public | — | Public |
Provider 
Founded 1958
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Private
Provider AbbVieabbvie.com250k raised · Public
Founded 2013
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 1885
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership —
Provider 
Founded 2014
Sells To Enterprise
Pricing Model Recurring
Ownership Public